Osmetech Shareholders Approve US IPO | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A majority of Osmetech's shareholders have approved the firm's plans to proceed with an initial public offering and other proposals, according to a notice posted on the London Stock Exchange.

Last month, Osmetech said that it had filed with the US Securities and Exchange Commission for the IPO under the name of its newly proposed parent, GenMark Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.